Middle East Respiratory Syndrome (MERS) virus-pathophysiological axis and the current treatment strategies

Alnuqaydan, Abdullah M. and Almutary, Abdulmajeed G. and Sukamaran, Arulmalar and Yang, Brian Tay Wei and Lee, Xiao Ting and Lim, Wei Xuan and Ng, Yee Min and Ibrahim, Rania and Darmarajan, Thiviya and Nanjappan, Satheeshkumar and Chellian, Jestin and Candasamy, Mayuren and Madheswaran, Thiagarajan and Sharma, Ankur and Dureja, Harish and Prasher, Parteek and Verma, Nitin and Kumar, Deepak and Palaniveloo, Kishneth and Bisht, Dheeraj and Gupta, Gaurav and Madan, Jyotsana R. and Singh, Sachin Kumar and Jha, Niraj Kumar and Dua, Kamal and Chellappan, Dinesh Kumar (2021) Middle East Respiratory Syndrome (MERS) virus-pathophysiological axis and the current treatment strategies. AAPS PharmSciTech, 22 (5). ISSN 1530-9932, DOI https://doi.org/10.1208/s12249-021-02062-2.

Full text not available from this repository.


Middle East respiratory syndrome (MERS) is a lethal respiratory disease with its first case reported back in 2012 (Jeddah, Saudi Arabia). It is a novel, single-stranded, positive-sense RNA beta coronavirus (MERS-CoV) that was isolated from a patient who died from a severe respiratory illness. Later, it was found that this patient was infected with MERS. MERS is endemic to countries in the Middle East regions, such as Saudi Arabia, Jordan, Qatar, Oman, Kuwait and the United Arab Emirates. It has been reported that the MERS virus originated from bats and dromedary camels, the natural hosts of MERS-CoV. The transmission of the virus to humans has been thought to be either direct or indirect. Few camel-to-human transmissions were reported earlier. However, the mode of transmission of how the virus affects humans remains unanswered. Moreover, outbreaks in either family-based or hospital-based settings were observed with high mortality rates, especially in individuals who did not receive proper management or those with underlying comorbidities, such as diabetes and renal failure. Since then, there have been numerous reports hypothesising complications in fatal cases of MERS. Over the years, various diagnostic methods, treatment strategies and preventive measures have been strategised in containing the MERS infection. Evidence from multiple sources implicated that no treatment options and vaccines have been developed in specific, for the direct management of MERS-CoV infection. Nevertheless, there are supportive measures outlined in response to symptom-related management. Health authorities should stress more on infection and prevention control measures, to ensure that MERS remains as a low-level threat to public health.

Item Type: Article
Uncontrolled Keywords: Middle East respiratory syndrome (MERS);Endemic; Transmission;Lower respiratory tract (LRT) diseases;Vaccine
Subjects: R Medicine
R Medicine > RA Public aspects of medicine
R Medicine > RB Pathology > Theories of disease. Etiology. Pathogenesis
R Medicine > RM Therapeutics. Pharmacology
Divisions: Deputy Vice Chancellor (Research & Innovation) Office > Institute of Ocean and Earth Sciences
Depositing User: Ms Zaharah Ramly
Date Deposited: 15 Sep 2022 06:12
Last Modified: 15 Sep 2022 06:12
URI: http://eprints.um.edu.my/id/eprint/34586

Actions (login required)

View Item View Item